Posts

Big Pharma’s 10 Highest-Paid CEOs of 2025: Key Figures and Compensation Ranges

on

How LB Pharmaceuticals Rode Brutal Capital Markets to One of 2025's Most Successful IPOs

on

FDA Policy Tracker: 2025 Was a Year of Change

on

Spotlight On: Five Key FDA Approvals of 2025

on

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

on

The 5 Most Painful Clinical Trial Failures of 2025

on

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

on

Health tech investors are getting creative with exits in 2025

on

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

on

Spotlight On: VC Deal Flow – October's Haul Sets 2025 up to Run Rings Around Previous Year

on

FDA Drug Approvals in 2025 Remain Within Recent Averages Amid Agency Upheaval

on

How Past Endpoints 11 Winners Fared During the 2025 Biotech Downturn

on

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

on

Recent Developments in Building Measurable Patient Support Programs (2025)

on

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

on

ASCO 2025: Amgen’s Imdelltra Cuts Small Cell Lung Cancer Death Risk by 40% Versus Chemo

on

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

on

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

on

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

on

FDA to Decide on Merck's Subcutaneous Keytruda in September 2025

on